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helhigh Injectable Stented Pulmonic Valve
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able online.
ignificant pulmonary regurgitation (PR) is common after
surgical or percutaneous treatment of pulmonary stenosis
and tetralogy of Fallot (TOF) and leads to significant late
morbidity and mortality.1 Optimal timing of pulmonary
alve replacement (PVR) and procedures minimizing surgical trauma
re therefore important.2 The new Shelhigh Injectable Stented Pul-
onic Valve NR4000-PA MIS (Shelhigh Inc, Union, NJ) offers the
ossibility of PVR without cardiopulmonary bypass (CPB). Here we
eport our early experience with the first clinical use of this new
evice.
atients and Methods
Patients. Four patients, median age 14.8 (11.2-40) years, re-
eived PVR with the Shelhigh Injectable Stented Pulmonic Valve.
hree had PR following transannular patch or commissurotomy at
revious TOF repair, and 1 after repair of congenital pulmonary
tenosis. Median interval between initial repair and actual surgery
as 14 (10.4-33.4) years. All patients had exercise intolerance and
yspnea on exertion; all presented with severe PR, progressive RV
ilatation, impaired RV function, and 2 with impaired left ventric-
lar function. Informed consent for compassionate use under CE
egulations were obtained from all patients.
Device description and implantation technique. The Shel-
igh Injectable Stented Pulmonic Valve, an evolution of the Shelhigh
ulmonic Valved No-React-treated Conduit NR4000-PA, consists of
porcine pulmonic valve mounted inside a self-expandable stent
overed by No-React-treated pericardium (Figure 1, A and B),
vailable in sizes 17 to 29 mm. Through a median sternotomy main
ulmonary artery (MPA), bifurcation and right ventricular outflow
ract (RVOT) were dissected free and 2 purse-string sutures were
laced on the distal RVOT. For preinjection preparation, the
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ressed with the supplied
oop restrictor, slid into the
arrel of the delivery trocar
Figure 1, C), and the intro-
ucer tip secured on the barrel
Figure 1, D). After hepa-
inization (Liquemin, Roche Pharma Inc., Reinach, Switzerland;
0 IU/kg body weight), the delivery trocar was introduced through
small incision across the purse-string sutures and the barrel
urther advanced through the introducer tip into the MPA (Figure
). Under digital control, the valve was ejected from the barrel
hile the delivery trocar system was slowly withdrawn. After de-
loyment, the valve was secured with several transmural sutures
laced at the proximal and distal rim of the valve. After assessment of
he valve performance, the chest was closed in a routine fashion.
esults
alve insertion, delivery, and placement were successful and he-
odynamic performance was excellent in all patients (Figure E3,
able E1). Before valve insertion, 1 patient required additional
eduction plasty of the severely enlarged MPA (33 mm). Early
ecovery was uneventful and all patients were discharged home.
owever, 1 patient required reoperation 2 months later due to valve
igration with severe MPA obstruction and recurrent PR. This failure
s explained by a dilated and conical-shaped MPA (maximal diameter
5 mm), which had not been reduced at the time of valve insertion,
nd insufficient transmural valve fixation. Routine echocardiographic
ollow-up after 4, 9, 12, and 18 (median 12.2, range 4.3-18.2) months
howed good results in the remaining 3 patients with low gradients in
ll and moderate paravalvular PR in 1. RV function has recovered to
ubnormal values in all but the 1 patient with moderate PR. All
atients were in New York Heart Association functional class I at the
atest follow-up.
iscussion
ecause patients with TOF or isolated congenital pulmonary ste-
osis usually need several cardiac reinterventions in the long term,
inimizing procedural invasiveness and risks is mandatory. To
ate, surgeons reduce the impact of repetitive surgery by performing
ost of these procedures on a beating heart under normothermia
ith very low early mortality and morbidity in recent years. The
ew Shelhigh Injectable Stented Pulmonic Valve now offers the
dvantage of avoiding completely CPB use. Compared with the
ercutaneous approach,3 it offers several advantages. All implant
izes needed are available and the procedure is not limited by small
atheters or access vessel diameters. Furthermore, No-React-
reated biologic implants resist calcification and degeneration with
xcellent results4 in contrast to the percutaneously used conduit.5
Dr Berdatdditionally, concomitant proced
y 2006ures frequently necessary on the
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Brief CommunicationsVOT or the pulmonary artery can be performed simultaneously.
reoperatively, RVOT and pulmonary artery morphology has to be
tudied carefully by transthoracic echocardiography and magnetic
esonance imaging to determine prosthetic valve size and decide
n additional procedures. Our early experience shows that reduc-
ion plasty of an enlarged MPA of 28 mm and semicircular
xation of the implant are mandatory to ensure a stable position
nd prevent paravalvular regurgitation. Device handling and valve
mplantation, however, have proven easy and straightforward. The
ollow-up will provide the necessary information on mid- to long-
erm performance of the Shelhigh Injectable Stented Pulmonic
igure 1. A, The Shelhigh Injectable Stented Pulmonic Valve
evice system. B, Detailed view of the Stented Pulmonic Valve. C,
he valve is gently compressed and slid into the barrel of the
elivery trocar. D, Barrel with loaded valve and mounted inser-
ion tip.alve.
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1Figure E1. A, Postoperative chest radiograph showing the stented valve in correct position (arrow). B, Postoper-
ative transthoracic echocardiography showing excellent valve function (arrow) without regurgitation or gradient.
ABLE E1. Valve hemodynamics and perioperative data
Patient
Valve
size (mm)
Operation
time (min)
Peak
gradient*
Pulmonary
regurgitation* LOS
1 23 160 4.7 None 8
2 25 150 7.5 Trace 7
3 29 170 11 None 7
4 23 280 5 None 8Echocardiographic and invasive measurements. LOS, length of hospital stay in days.
193.e1 The Journal of Thoracic and Cardiovascular Surgery ● May 2006
